Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Source: Globenewswire
- Lawsuit Background: Soleno Therapeutics, Inc. (NASDAQ: SLNO) faces a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Soleno made materially false statements regarding its DCCR drug's Phase 3 clinical trial, failing to disclose serious safety concerns, which could undermine investor confidence in the company's future prospects.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to revelations of issues in the clinical trial, reflecting heightened market concerns about the company's viability.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for free legal consultations, highlighting the potential financial losses and risks associated with the ongoing litigation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
